Clinical trials

Human heart
#Cardiovascular disease #Clinical trials #Drug development #Drug discovery

Can human mini-Hearts advance cardiovascular drug development?

By Ronald A Li, PhD, CEO and Co-Founder, Medera, and Kevin D Costa, PhD, Co-Founder, Novoheart. Recent NIH policy prioritising the use of New Approach Methodologies (NAMs) as alternatives to laboratory animals in all new funding opportunities marks a seismic shift in how biomedical research will be conducted. For a… Read More

#Exclusive Content

Vaccine
#Clinical trials #Drug discovery #Immunology / Virology & Vaccines #Vaccines

Human challenge trial for pneumococcal vaccine launches in Malawi  

The first clinical trials for a new vaccine targeting pneumococcal disease in people in Malawi have been launched.  The human challenge trial will enrol 400 people in Malawi making it the biggest trial the country has seen to date.   The launch of the trial comes… Read More

#News

Patient speaking to psychiatrist
#Clinical trials #Mental health #Psychiatry #UK

First NHS-embedded clinical trial site for mental health launches

The UK’s first fully NHS-embedded commercial research for brain and mental health conditions has been launched by Clerkenwell Health.   Developed in partnership with Rotherham Doncaster and South Humber (RDaSH) NHS Foundation Trust, the initiative aims to set a new standard for how trials are delivered in the… Read More

#News

MHRA
#Biogen #Clinical trials #Mental health #MHRA #Regulatory #UK

Treatment for post-natal depression authorised in UK

The first targeted treatment for post-natal depression (PND) has been authorised for use in the UK through the approval of Biogen’s zuranolone by the Medicines and Healthcare Products Regulatory Agency (MHRA). Biogen state that the marketing authorisation by the MHRA addresses a critical, unmet need in maternal health due to… Read More

#News

#Clinical trials #Drug discovery #Funding #Immunology / Virology & Vaccines #Obesity

This week in drug discovery 1-5 September

News round-up for 1-5 September by DDW Editor Reece Armstrong. There have been a number of stories this week promoting promising science in the areas of obesity and cardiology, along with a partnership to advance vaccine science. The top stories Research programme represents a “new frontier in vaccine… Read More

#News

Vaccine
#Clinical trials #Drug discovery #Infectious diseases #Vaccines

Research programme represents a “new frontier in vaccine science” 

The UK’s University of Oxford, through its strategic partnership with the Ellison Institute of Technology (EIT), has received research funding of £118 ($159.7) million to launch an ambitious new programme of vaccine research.  Led by the Oxford Vaccine Group, the new initiative based in the University – CoI-AI (Correlates of… Read More

#Business & Investment #News

Eye health ophthalmology
#Clinical trials #Drug discovery #Gene therapy #Ophthalmology

Advancing gene-agnostic therapies for inherited retinal diseases 

DDW’s Megan Thomas speaks with Dr Arun Upadhyay, Chief Scientific Officer, Head of Research & Development at Ocugen, about the development of gene-agnostic modifier therapies for inherited retinal diseases, highlighting pathway discovery, preclinical models, dosing strategies, biomarker integration, and the potential expansion of this approach beyond ophthalmology.  MT: How does… Read More

#Exclusive Content #News

FDA
#Autoimmune disease #Clinical trials #Drug approvals #FDA

FDA approves first BTK inhibitor for immune thrombocytopenia 

The US Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.   The approval was based on the pivotal LUNA 3 Phase III study, in which Wayrilz met the… Read More

#News

Red blood cells
#Cardiovascular disease #Clinical trials #Drug development

Baxdrostat offers hope for stubborn high blood pressure 

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high despite medication, according to the results of a Phase III clinical trial.  The international BaxHTN trial, led by Professor Bryan Williams, UCL Institute of Cardiovascular Science, and sponsored by… Read More

#News

#Clinical trial design #Clinical trials #Rare disease

Clinical trials in rare and life-limiting diseases

Dr Tony Lockett, Chief Medical Officer at Nevrargenics, explores the future of clinical trials in rare diseases. Clinical trials are in crisis. Over 80% of clinical trials over-run in costs and time and 60% of trials also do not make their endpoint. In this circumstance, it is hardly surprising that… Read More

#Exclusive Content

#Clinical trials #Drug discovery #National Institute for Health Research #UK

New network to boost industry clinical trials in the UK

The National Institute for Health and Care Research (NIHR) has awarded £6.5 (£8.7) million, funded jointly through a public-private partnership with the pharmaceutical industry, to establish a UK-wide Commercial Research Delivery Centre (CRDC) Network.   The new Network will provide strategic coordination of all 21 CRDCs across the… Read More

#News

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #Drug discovery

The next generation of clinical trials with AI

Niven R Narain, President and CEO, BPGbio, looks at how biology-first Bayesian causal AI is redefining success in drug development. From using AI-based computational modelling to phase out animal testing for monoclonal antibodies1, to deploying its proprietary large language model-powered tool, Elsa, to read, write, and summarise regulatory documents—reducing review time… Read More

#Exclusive Content

#Clinical trials #Diabetes #Duchenne muscular dystrophy #HIV #Immunology / Virology & Vaccines #Obesity #Oncology

This week in drug discovery (4-8 August) 

News round-up for 4-8 August by DDW Senior Digital Content Editor Diana Turner. In the week that the US Department of Health and Human Services cancelled multiple programmes investigating mRNA vaccines, a number of other clinical trials have made the headlines. The top stories:… Read More

#News

#Cardiometabolic diseases #Clinical trials #Corteria Pharmaceuticals #Heart failure #Obesity

Corteria Pharmaceuticals initiates two trials with its CRF2 agonists

Corteria Pharmaceuticals has initiated a Phase II trial in heart failure and Phase I trial in obesity with its first-in-class corticotropin‑releasing factor receptor 2 (CRF2) agonists, COR‑1167 and COR‑1389.  CRAFT-WHF Phase II trial of COR-1167 in worsening heart failure COR-1167… Read More

#News

#Clinical trials #Next generation sequencing #Oncology #Sequencing

Bridging the clinical trials gap in cancer

Kathy Davy, President of Next-Generation Clinical Sequencing Division, Thermo Fisher Scientific, asks how clinical trials in cancer can be accelerated through the use of rapid next-generation sequencing (NGS) technology. Every cancer diagnosis marks the beginning of an urgent and often overwhelming journey for patients and their families. And in some… Read More

#Business & Investment #Cancer Research #Exclusive Content

Map of Europe
#Clinical trials #EFPIA #Europe #European Commission #European Union

Group warns European clinical research is at risk

A broad group of 14 organisations, working in the European clinical trial sector, have issued a warning that without urgent implementation of the Life Science Strategy (LSS), Europe’s clinical trial eco-system is in a perilous situation.  The stakeholders—including academic and industry sponsors, investigators, and professional societies—formed earlier this year to… Read More

#Business & Investment #News